Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer

Journal of Clinical Pathology

Volumn 60, Issue 8, 2007, Pages 885-895

  Esposito, Irene ^a   Kleeff, Jörg ^a   Abiatari, Ivane ^a   Shi, Xined ^a   Giese, Nathalia ^a   Bergmann, Frank ^a   Roth, Wilfried ^a   Friess, Helmut ^a   Schirmacher, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN 2; MESSENGER RNA;

ADULT; AGED; ANOIKIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMA IN SITU; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA IN SITU; CELL LINE, TUMOR; CHRONIC DISEASE; CYSTS; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS;

EID: 34547770901     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.038257     Document Type: Article

References (47)

1. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003;2:6.
2. Ozawa F, Friess H, Zimmermann A, et al. Enhanced expression of Silencer of death domains (SODD/BAG-4) in pancreatic cancer. Biochem Biophys Res Commun 2000;271:409-13.
3. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001;163:71-81.
4. Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol 2001;194:444-50.
5. Friess H, Lu Z, Andren-Sandberg A, et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998;228:780-7.
6. Friess H, Lu Z, Graber HU, et al. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998;43:414-21.
7. Wright CW, Duckett CS. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 2005;115:2673-8.
8. Yang Y, Fang S, Jensen JP, et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000;288:874-7.
9. Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006;281:3254-60.
10. Chu ZL, McKinsey TA, Liu L, et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 1997;94:10057-62.
11. Wang CY, Mayo MW, Korneluk RG, et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
12. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999;93:3601-9.
13. Imoto I, Yang ZQ, Pimkhaokham A, et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 2001;61:6629-34.
14. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555-62.
15. Esposito I, Penzel R, Chaib-Harrireche M, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006;208:673-85.
16. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. Mol Cancer 2003;2:15.
17. Liu Z, Li H, Derouet M, et al. ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem 2005;280:37383-92.
18. Shergill IS, Shergill NK, Arya M, et al. Tissue microarrays: a current medical research tool. Curr Med Res Opin 2004;20:707-12.
19. Sobin L, Wittekind C. TNM classification of malignant tumours, 6th edn. New York: Wiley-Liss, 2002.
20. Klöppel G, Hruban R, Adler G, et al. Tumours of the exocrine pancreas. In: Hamilton S, Aaltonen L, eds. World Health Organization classification of tumours.Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000:220.
21. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-86.
22. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
23. Neoptolemos JP, Cunningham D, Friess H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003;14:675-92.
24. Knaebel HP, Marten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI: study protocol [ISRCTN62866759]. BMC Cancer 2005;5:37.
25. Giese NA, Raykov Z, DeMartino L, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 2002;9:432-42.
26. Solcia E, Capella C, Klöppel G. Tumors of the pancreas. In: Rosai J, Sobin L, eds. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology, 1997.
27. Vischioni B, van der Valk P, Span SW, et al. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2006;37:78-86.
28. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996;379:349-53.
29. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
30. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586-94.
31. Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001;92:271-8.
32. Tonini G, Vincenzi B, Santini D, et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer 2005;92:2225-32.
33. Kami K, Doi R, Koizumi M, et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 2005;138:299-305.
34. Tsuji N, Asanuma K, Kobayashi D, et al. Introduction of a survivin gene-specific small inhibitory RNA inhibits growth of pancreatic cancer cells. Anticancer Res 2005;25:3967-72.
35. Yang L, Cao Z, Yan H, et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003;63:6815- 24.
36. Trauzold A, Schmiedel S, Roder C, et al. Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer 2003;89:1714-21.
37. Li Y, Jian Z, Xia K, et al. XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 2006;32:288-96.
38. Samuel T, Okada K, Hyer M, et al. cIAP1 localizes to the nuclear compartment and modulates the cell cycle. Cancer Res 2005;65:210-18.
39. Reed JC. The Survivin saga goes in vivo. J Clin Invest 2001;108:965-9.
40. Ferreira CG, van der Valk P, Span SW, et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 2001;12:799-805.
41. Imoto I, Tsuda H, Hirasawa A, et al. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002;62:4860-6.
42. Ponnelle T, Chapusot C, Martin L, et al. Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. Pathol Res Pract 2003;199:723-31.
43. Ekedahl J, Joseph B, Grigoriev MY, et al. Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 2002;279:277-90.
44. Vischioni B, Giaccone G, Span SW, et al. Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. Exp Cell Res 2004;298:535-48.
45. Lohr M, Kloppel G, Maisonneuve P, et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7:17-23.
46. Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpressian of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1-8.
47. Tan X, Egami H, Ishikawa S, et al. Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer. Int J Oncol 2004;25:1303-9.